Clinical trials: CAR T-cell Therapy
Lymphoma, Follicular, Lymphoma, Mantle-Cell
Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells
The purpose of this study is to assess long-term side effects from subjects who receive an Adicet Bio γδ CAR T cell product. Subjects will join this study once they complete the parent interventional study.
- Conditions
- Lymphoma, Follicular, Lymphoma, Mantle-Cell, Marginal Zone Lymphoma, Primary Mediastinal B-cell Lymphoma
- Trial name
- NCT04911478
- Testing
- ADI-001
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Adicet Therapeutics
Hematologic Malignancy, Solid Malignancy
A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies
This study will evaluate the long-term safety and efficacy of CRISPR CAR T cellular therapies
- Trial name
- NCT06208878
- Testing
- Non Interventional
- Where
- 24 sites in United States, Australia and 2 more
- Volunteers
- 70 people
- Sponsor
- CRISPR Therapeutics AG
Solid Tumor
A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors
This is a Phase I, FIH, open-label, multi-site, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of claudin 6 (CLDN6) chimeric antigen receptor T cells (CAR-T) with or without CLDN6…
- Trial name
- NCT04503278
- Testing
- CLDN6 CAR-T, CLDN6 uRNA-LPX/CLDN6 modRNA-LPX
- Where
- 12 sites in Australia, Germany and 2 more
- Volunteers
- 214 people
- Sponsor
- BioNTech Cell & Gene Therapies GmbH
Systemic Lupus Erythematosus, Lupus Nephritis
A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease
This is a phase 1 study of SYNCAR-001 + STK-009 in patients with severe, refractory systemic autoimmune rheumatic disease.
- Conditions
- Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis
- Trial name
- NCT06544330
- Testing
- SYNCAR-001, STK-009
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Synthekine
Advanced Hepatocellular Carcinoma (HCC), GPC3 Positive Hepatocellular Carcinoma
An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma
This study was a phase I safety and tolerability clinical trial conducted in a single-center, open-label, 3+3 design with dose escalation.
- Trial name
- NCT07493044
- Testing
- Super CAR-T
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Guangzhou FineImmune Biotechnology Co., LTD.
Acute Lymphoblastic Leukemia
CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia
This is a first-in-human study to evaluate the feasibility, safety and preliminary antitumor efficacy of autologous chimeric antigen receptor (CAR) T cells targeting both CD19 and CD22, manufactured with T-Charge(TM) process.
- Trial name
- NCT05168748
- Testing
- IMJ995 single agent
- Sponsor
- Novartis Pharmaceuticals
Childhood Acute Lymphoblastic Leukemia
CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia
In this study, CAR-T will be administered to children with acute lymphoblastic leukemia to explore the effect of CAR-T intervention time on the duration of complete remission and further verify the long-term safety and efficacy…
- Trial name
- NCT04626765
- Testing
- CD19 CAR-T, CD22 CAR-T, CD 19+22
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL
The purpose of this study is to evaluate the safety, recommended dose, and preliminary anti-tumor activity of WU-CART-007 in patients with relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic…
- Trial name
- NCT04984356
- Testing
- WU-CART-007
- Where
- 12 sites in United States, Australia and 2 more
- Volunteers
- 28 people
- Sponsor
- Allotera Therapeutics
Solid Tumor
An Exploratory Study by Fast CAR T Cells
The main goal of this trial is to evaluate the safety and tolerability of CAR T cell therapy for advanced solid tumors with positive mesothelin and MUC1.Patients were screened, peripheral blood mononuclear cells (PBMC) were…
- Trial name
- NCT06327997
- Testing
- Fast CAR T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Cell Therapy Group Co.,Ltd
Systemic Sclerosis, Scleroderma
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
RESET-SSc: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T cell therapy, in Subjects with Systemic Sclerosis
- Conditions
- Systemic Sclerosis, Scleroderma, Interstitial Lung Diseases
- Trial name
- NCT06328777
- Testing
- CABA-201
- Where
- 10 sites in United States
- Volunteers
- 37 people
- Sponsor
- Cabaletta Bio
Solid Tumor, Adult, Colorectal Cancer
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer
- Trial name
- BASECAMP-1 (NCT04981119)
- Testing
- Apheresis, Next Generation Sequencing (NGS), Long Range NGS HLA typing
- Where
- 16 sites in United States
- Volunteers
- 500 people
- Sponsor
- A2 Biotherapeutics Inc.
Acute Lymphoblastic Leukemia, Non Hodgkin Lymphoma
Safety and Efficacy Evaluation of Next-generation CD19-UCART
The purpose of this study is to evaluate the safety and efficacy of Next-generation CD19-UCART in patients with relapsed or refractory B-cell hematological malignancies.
- Trial name
- NCT05381181
- Testing
- CD19-UCART
- Volunteers
- 20 people
- Sponsor
- Bioray Laboratories
Relapsed/Refractory Multiple Myeloma
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
This trial is a Phase 1b/2, open-label, multicenter study of AZD0120, a CD19/BCMA dual CAR T-cell therapy, in adult subjects with relapsed/refractory multiple myeloma.
- Trial name
- DURGA-1 (NCT05850234)
- Testing
- AZD0120
- Where
- 36 sites in United States
- Volunteers
- 232 people
- Sponsor
- AstraZeneca
SLE, LN
A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
An Exploratory, Single-Arm, Open-Label, Dose-Escalation Study of the Safety, Tolerability, PK, PD, and Efficacy of Anti-CD19/BCMA Universal CAR-T Therapy RD06-05 in Autoimmune Diseases (including SLE/LN, AAV/AAGN, Anti-GBM, MN…
- Conditions
- SLE, LN, ANCA Associated Vasculitis, ANCA-Associated Glomerulonephritis
- Trial name
- NCT07203404
- Testing
- RD06-05 CART Cell Injection
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Nanjing Bioheng Biotech Co., Ltd.
Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome
Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
This is an investigator initiated trial to assess the efficacy and safety of BRL-301 in the relapse or refractory autoimmune diseases of China.
- Conditions
- Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy
- Trial name
- NCT05859997
- Testing
- BRL-301
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Bioray Laboratories
Newly Diagnosed Multiple Myeloma
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of standard induction regimens (IsaVRd and DRd) followed by AZD0120 versus standard induction regimens followed…
- Trial name
- DURGA-5 (NCT07764978)
- Testing
- AZD0120, Daratumumab, Dexamethasone
- Where
- 124 sites in United States, Australia and 13 more
- Volunteers
- 750 people
- Sponsor
- AstraZeneca
Small Cell Lung Cancer ( SCLC ), CAR-T Cell Therapy
TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC
This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of TC-D101 CAR-T cells in patients with DLL3-positive Relapsed/Refractory primary small…
- Trial name
- NCT07246304
- Testing
- TC-D101 CAR-T
- Where
- China
- Volunteers
- 24 people
- Sponsor
- TCRCure Biopharma Ltd.
Relapsed B Cell Acute Lymphoblastic Leukemia (ALL), Refractory B Cell Acute Lymphoblastic Leukemia (ALL)
CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
This is a single-arm, open-label, phase I study (safety and dose escalation) of autologous Chimeric Antigen Receptor (CAR) T-cells targeting CD19 in patients with relapsed/refractory B cell acute lymphoblastic leukemia (ALL).
- Trial name
- NCT04653493
- Testing
- CD19 CAR engineered autologous T-cells, Cyclophosphamide, Fludarabine
- Where
- 2 sites in Iran
- Volunteers
- 22 people
- Sponsor
- Sabz Biomedicals
Hematological Malignancies
Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies
This is a long-term follow-up study for participants treated with Galapagos (GLPG) CAR T-cell therapies to evaluate the long-term safety and efficacy of GLPG CAR T-cell products for 15 years post infusion.
- Trial name
- Hesperia (NCT06652633)
- Testing
- GLPG CAR T-cell therapy
- Where
- 11 sites in United States, Belgium and 3 more
- Volunteers
- 546 people
- Sponsor
- Lakefront Biotherapeutics NV
Prostatic Neoplasms, Castration-Resistant, Neoplasms by Histologic Type
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC and SGC.
- Conditions
- Prostatic Neoplasms, Castration-Resistant, Neoplasms by Histologic Type, Neoplasms, Prostate, Prostate Cancer
- Trial name
- NCT04249947
- Testing
- P-PSMA-101 CAR-T cells, Rimiducid
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- Poseida Therapeutics, Inc.